Security key
03969K108
ARCUTIS BIOTHERAPEUTICS INC - COMMON STOCK (ARQT)
CUSIP: 03969K108
Q1 2022 13F Holders as of 31 Mar 2022
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 48,307,139
- Total 13F value
- $929,780,885
- Share change
- -6,428,138
- Put/Call ratio
- 13%
- SEC-reported price per share
- $19.26
- Number of holders
- 106
- Value change
- -$136,426,148
- Number of buys
- 50
- Number of sells
- 35
- Shares outstanding
- 123,890,213
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2022
Institutions
106
Top holders
10
ARQT full security history
Ownership snapshot
Full 13F holder table
Arcutis Biotherapeutics, Inc. SEC filings
Arcutis Biotherapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ARQT - ARCUTIS BIOTHERAPEUTICS INC - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FRAZIER MANAGEMENT LLC
Disclosed value leader
FRAZIER MANAGEMENT LLC
Comparable rows
15/15
Latest evidence
31 Dec 2021
13F
Lead comparable stake: 6.8%
Showing 1-6 of 15 holder rows.
Quick read
FRAZIER MANAGEMENT LLC leads the comparable SEC ownership view at 6.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FRAZIER MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
FRAZIER MANAGEMENT LLC
6.8%
FMR LLC
6.1%
ORBIMED ADVISORS LLC
4.9%
BlackRock Finance, Inc.
3.5%
Bain Capital Life Sciences Invest...
3.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FRAZIER MANAGEMENT LLC |
13F
Company
|
6.8%
|
$174,926,000
8,434,232 shares
|
— | 31 Dec 2021 |
| FMR LLC |
13F
Company
|
6.1%
|
$156,467,000
7,544,212 shares
|
— | 31 Dec 2021 |
| ORBIMED ADVISORS LLC |
13F
Company
|
4.9%
|
$125,972,000
6,073,850 shares
|
— | 31 Dec 2021 |
| BlackRock Finance, Inc. |
13F
Company
|
3.5%
|
$89,471,000
4,313,864 shares
|
— | 31 Dec 2021 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
3.2%
|
$82,531,000
3,979,292 shares
|
— | 31 Dec 2021 |
| Point72 Asset Management, L.P. |
13F
Company
|
2.1%
|
$54,840,000
2,644,177 shares
|
— | 31 Dec 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
106
Shares
48,307,139
Rows available
106
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2022 vs Q1 2022 Across Filers
Q1 2022 holders
106
Q1 2022 holders
106
Holder diff
0
| Investor | Q1 2022 Shares | Q1 2022 Shares | Share Diff | Share Chg % | Q1 2022 value | Q1 2022 value | Value change | Value Chg % |
|---|